MRA Or Not, Swiss Medtech Industry Urges Maximum Convergence With EU MDR
Swiss domestic medtech manufacturers reluctantly accept Switzerland’s new status as a third country to the EU, but the Swiss industry is anxious that new national regulations do not impose higher hurdles than the EU MDR. At present, there is a risk of that happening.
You may also be interested in...
The UK MedTech Directorate has issued its much-awaited medical technology strategy for improving supply resilience and encouraging innovative and dynamic markets and sector diversity.
All eyes were on the European Commission in January as it edged closer to adopting new legislation that will see the Medical Device Regulation transition deadlines extended.
One outcome of last year’s public consultation on UK MHRA fees is a hefty uplift in charges payable by medtech manufacturers in 2023, beyond which the agency is keen to pursue a new fees and charges plan.